SLC5A2 and chronic kidney disease: The updated NICE CKD guidelines in 2021 included the use of the KFRE and sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve individualized and population level care for CKD and the risk of both progression to KRT and cardiovascular events [1].